



**DATE: DECEMBER 30, 2020**

**SUBJECT: NEUROTROPE, INC. – CONTRACT ADJUSTMENT**  
**OPTION SYMBOL: 12/2/20 – NTRP remained NTRP**  
**12/3/20 – NTRP became PTPI1**

**DATE: 12/2/20**  
**\*\*\* UPDATE \*\*\***

**Contract Adjustment**

**DATE:** December 2, 2020

**OPTION SYMBOL:** 12/2/20 – NTRP remained NTRP (with adjusted deliverable described below)  
12/3/20 – NTRP became PTPI1

**STRIKE DIVISOR:** 1

**CONTRACTS  
MULTIPLIER:** 1

**NEW MULTIPLIER:** 100 (e.g., a premium of 1.50 yields \$150; a strike of 20 yields \$2,000.00)

**NEW DELIVERABLE  
PER CONTRACT:** 1) 20 Petros Pharmaceuticals, Inc. (PTPI) Common Shares  
2) **20 Synaptogenix, Inc. (SNPX) Common Shares**

**SETTLEMENT  
ALLOCATION:** PTPI: 95%  
**SNPX: 5%**

**CUSIPS:** PTPI: 71678J100  
**SNPX: 87167T102**

THE SETTLEMENT ALLOCATION OF THE TOTAL STRIKE PRICE AMOUNT IS BEING PROVIDED SOLELY FOR THE PURPOSE OF THE INTERFACE BETWEEN OCC AND THE NATIONAL SECURITY CLEARING CORPORATION (NSCC), AND IS NOT INTENDED TO BE USED FOR ANY OTHER PURPOSE, TRANSACTION OR CUSTOMER ACCOUNT STATEMENTS.

**PRICING**

The underlying price for PTPI1 will be determined as follows:

$$PTPI1 = 0.20 (PTPI) + 0.20 (SNPX)$$

## **SETTLEMENT**

The PTPI component of the PTPI1 deliverable will continue to settle through National Securities Clearing Corporation (NSCC). The **SNPX** component of the PTPI1, which was subject to delayed settlement from December 2, 2020 through December 29, 2020, will now settle at NSCC. Now that the trading status has been determined, OCC will require Put exercisers and Call assignees to deliver the appropriate number of SNPX shares.

## **BACKGROUND**

On November 25, 2020, Shareholders of Neurotrope, Inc. (NTRP) approved a series of proposed mergers with subsidiaries of Metuchen Pharmaceuticals, LLC, to form a combined company, Petros Pharmaceuticals, Inc. (PTPI). The mergers were subsequently consummated before the open on December 2, 2020. As a result, each existing NTRP Common Share were converted into the right to receive 0.20 PTPI Common Shares.

Petros Pharmaceuticals, Inc. Common Shares are trading on the Nasdaq Stock Market under the trading symbol "PTPI".

**Immediately following the closing of the mergers, NTRP spun off 0.20 Neurotrope Bioscience, Inc. (SpinCo) shares per NTRP share held.**

**The SpinCo shares have begun trading on an over-the-counter market under the new name and ticker symbol Synaptogenix, Inc. (SNPX).**

## **DISCLAIMER**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

**ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.**

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email [investorservices@theocc.com](mailto:investorservices@theocc.com). Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).